Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Nivolumab/Ipilimumab Demonstrates Durable OS Benefit in Malignant Pleural Mesothelioma

August 11, 2020 By Thomas Lamb

[ An Opdivo plus Yervoy combination ] significantly improved overall survival (OS) versus chemotherapy in the first-line treatment of patients with unresectable malignant pleural mesothelioma, according to findings from a prespecified analysis of the phase 3 CheckMate-743 trial (NCT02899299) that were presented during the 2020 International … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, Opdivo, Yervoy

Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis

July 17, 2020 By Thomas Lamb

Introduction:  The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is a matter of debate. We aimed to clarify whether MPM patients with loss of BAP1 expression have better overall survival (OS) compared to BAP1 positive patients. Methods:  [ BRCA1 associated protein-1 (BAP1) ] … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma diagnosis, mesothelioma treatments

Study finds drug beneficial for shrinking mesothelioma tumors

July 13, 2020 By Thomas Lamb

A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be beneficial in a small study involving ten patients. The results, which appeared July 1, 2020, in Science Translational Medicine, suggest that the drug LMB-100 could prolong the life of some patients with advanced … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Immunotherapy, mesothelioma, mesothelioma treatments

[Transforming Growth Factor Alpha] Promotes Chemoresistance of Malignant Pleural Mesothelioma

June 25, 2020 By Thomas Lamb

Background: There is no standard chemotherapy for refractory or relapsing malignant pleural mesothelioma (MPM). Our previous reports nevertheless indicated that a combination of an anthracycline (doxorubicin) and a lysine deacetylase inhibitor (valproic acid, VPA) synergize to induce the apoptosis of MPM cells and reduce tumor growth in mouse … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, malignant pleural mesothelioma (MPM), mesothelioma treatments

Bristol Myers Squibb’s Opdivo-Yervoy combo helps mesothelioma patients live longer

April 29, 2020 By Thomas Lamb

Bristol-Myers Squibb’s Opdivo-Yervoy combo is awaiting some critical decisions in non-small cell lung cancer, but in the meantime, it’s making its mark in a smaller indication, too. The immuno-oncology [ Opdivo-Yervoy combo ] topped chemo at extending the lives of phase 3 trial patients with previously untreated malignant pleural mesothelioma … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma

April 2, 2020 By Thomas Lamb

Aims:  Malignant pleural mesothelioma (MPM) is a rare malignancy with dismal prognosis. While [ epithelioid malignant pleural mesothelioma ] is associated with more favorable outcome, additional factors are needed to further stratify prognosis and to identify patients who can benefit from multimodal treatment. As [ epithelioid malignant … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

The Role of Neoadjuvant Chemotherapy in Patients with Resectable Malignant Pleural Mesothelioma – An Institutional and National Analysis

March 11, 2020 By Thomas Lamb

BACKGROUND:  There is no standard of care with respect to the use of neoadjuvant chemotherapy (NAC) in resectable malignant pleural mesothelioma (MPM). We performed an intention-to-treat analysis with data from a single institution and the National Cancer Database (NCDB) to identify whether the use of [ neoadjuvant chemotherapy (NAC) ] impacts … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments

Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature

March 6, 2020 By Thomas Lamb

Background:  Malignant mesothelioma of the tunica vaginalis is a rare tumour which comprises less than 1% of all mesotheliomas. Case presentation:  69-years old patient with painful hard mass and hydrocele in the right scrotum to whom a right hydrocelectomy was performed. Any history of scrotal trauma or exposure to asbestos was not … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant mesothelioma, mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Lurbinectedin as Second- or Third-Line Palliative Therapy in Malignant Pleural Mesothelioma

February 20, 2020 By Thomas Lamb

BACKGROUND: Systemic second- and third-line therapies for malignant pleural mesothelioma (MPM) result in a median progression-free survival (mPFS) of <2 months and median overall survival (mOS) of 6-9 months. Lurbinectedin binds to the regulatory region DNA whilst inhibiting tumour-associated macrophage transcription. In early trials, … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: lurbinectedin, malignant pleural mesothelioma (MPM), mesothelioma treatments

Malignant Diffuse Mesothelioma in Women — A Study of 354 Cases

February 11, 2020 By Thomas Lamb

We reviewed 354 cases of malignant diffuse mesothelioma (MM) in women from a database of 2858 histologically confirmed MM cases. There was a pleural predominance with 78% [ pleural malignant mesothelioma ] and 22% [ peritoneal malignant mesothelioma ]. The pleural tumors consisted of 72% epithelioid, 19% biphasic, and 9% sarcomatoid variant. The … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: asbestos exposure, asbestos fibers, diffuse peritoneal malignant mesothelioma (DPM), malignant pleural mesothelioma (MPM), mesothelioma, secondhand asbestos exposure

« Previous Page
Next Page »

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Who Was Exposed to Asbestos
  • NC Asbestos Exposure Sites
  • Asbestos-Contaminated Talc
  • Asbestos Diseases
  • Legal Compensation
  • Free Case Evaluation
  • Frequently Asked Questions
  • About Our Law Firm
  • Attorney Tom Lamb
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2021 · Law Offices of Thomas J. Lamb, P.A.